Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of “Hold” from Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD) have earned an average rating of “Hold” from the six analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $8.00.

A number of equities research analysts have issued reports on IVVD shares. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Invivyd in a report on Tuesday, June 9th. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating on shares of Invivyd in a report on Thursday, May 14th.

Institutional Investors Weigh In On Invivyd

Several hedge funds have recently made changes to their positions in IVVD. Perceptive Advisors LLC bought a new stake in shares of Invivyd in the fourth quarter valued at about $53,809,000. BVF Inc. IL bought a new stake in shares of Invivyd in the fourth quarter valued at about $48,227,000. RA Capital Management L.P. bought a new stake in shares of Invivyd in the third quarter valued at about $18,831,000. ADAR1 Capital Management LLC bought a new stake in shares of Invivyd in the third quarter valued at about $8,108,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Invivyd by 28.2% in the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after buying an additional 7,160,065 shares during the period. Institutional investors own 70.36% of the company’s stock.

Invivyd Price Performance

IVVD stock opened at $0.77 on Friday. Invivyd has a 52-week low of $0.48 and a 52-week high of $3.07. The company has a 50-day moving average of $1.32 and a two-hundred day moving average of $1.77. The stock has a market capitalization of $226.85 million, a price-to-earnings ratio of -2.48 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The firm had revenue of $13.74 million for the quarter, compared to the consensus estimate of $18.04 million. Equities analysts expect that Invivyd will post -0.5 EPS for the current fiscal year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.